---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Indication"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Indication. Topics: Indication submitted in the BLA: treatment of Huntington's disease under the accelerated approval pathway, Investigational status: no approved indication, and Population studied: adults aged 25 to 65 years with early manifest Huntington's disease. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/indication"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Indication submitted in the BLA: treatment of Huntington's disease under the accelerated approval pathway

> “today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway.”

Source: [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics)

<a id="topic-2.1.2.5-2"></a>

### Investigational status: no approved indication

> “AMT-130 is an investigational agent currently being studied in the treatment of Huntington’s Disease.”
> “Its safety and efficacy have not been established and it has not been approved by the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), or any other regulatory body.”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-2.1.2.5-3"></a>

### Population studied: adults aged 25 to 65 years with early manifest Huntington's disease

> “We are currently conducting a multi-center randomized, controlled Phase I/II clinical trial for AMT-130 in the U.S. (the “U.S. study”), as well as an open-label Phase Ib/II study in Europe (the “European study”) with the same early-manifest criteria for Huntington’s disease as the U.S. study.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “Patients with a definitive clinical diagnosis of early manifest HD”
> “Males and females, between the ages of 25 to 65 years old”
> “CAG repeat expression of ≥40”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
